Publications by authors named "Ellen M Beauchamp"

7Publications

Identification and characterization of an alternative cancer-derived PD-L1 splice variant.

Cancer Immunol Immunother 2019 Mar 18;68(3):407-420. Epub 2018 Dec 18.

Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.

View Article and Find Full Text PDF
March 2019

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.

ACS Chem Biol 2015 Dec 25;10(12):2687-96. Epub 2015 Sep 25.

Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts, United States.

View Article and Find Full Text PDF
December 2015

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.

Mol Cancer Ther 2015 Oct 23;14(10):2382-2389. Epub 2015 Jul 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article and Find Full Text PDF
October 2015

The Prochlorococcus carbon dioxide-concentrating mechanism: evidence of carboxysome-associated heterogeneity.

Photosynth Res 2015 Jan 6;123(1):45-60. Epub 2014 Sep 6.

Department of Biology, Williams College, Thompson Biology Lab 214, Williamstown, MA, 01267, USA,

View Article and Find Full Text PDF
January 2015

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.

Mol Cancer Ther 2014 Feb 2;13(2):475-82. Epub 2013 Dec 2.

Corresponding Author: Peter S. Hammerman, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 810A, Boston, MA 02215.

View Article and Find Full Text PDF
February 2014

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Cancer Discov 2013 Dec 27;3(12):1355-63. Epub 2013 Sep 27.

Departments of 1Medicine and 2Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Ludwig Institute for Cancer Research; 5Department of Neurosurgery, Massachusetts General Hospital; 6Belfer Institute for Applied Cancer Science; 7Department of Pathology, Brigham and Women's Hospital, Boston; 8Broad Institute, Cambridge, Massachusetts; 9UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and 10Department of Molecular Pharmacology and Therapeutics, Oncology Institute, Loyola University, Chicago, Illinois; 11Department of Physiology, University of Valencia, Valencia, Spain.

View Article and Find Full Text PDF
December 2013